z-logo
Premium
Nicotinamide reduces cyclooxygenase‐2 expression in HaCaT keratinocytes after ultraviolet‐B irradiation
Author(s) -
Monfrecola G.,
Di Caprio R.,
Balato N.,
Bevilacqua M. A.,
Iovine B.,
Lembo S.,
Balato A.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15338
Subject(s) - hacat , immunosuppression , nicotinamide , cancer research , cyclooxygenase , medicine , prostaglandin e2 , enzyme , prostaglandin , pharmacology , chemistry , dermatology , biochemistry , in vitro
In their interesting research letter, Chen et al. (2016 Apr 8. doi: 10.1111/bjd.14662)(1) described the protective effects of oral nicotinamide (NCT) for chemoprevention of non-melanoma skin cancers (NMSCs) in renal transplant recipients. We totally agree that NCT can represent a new opportunity for NMSC chemoprevention basing on its capability to preserve cellular energy reserve for ATP-dependent DNA repair as well as UV-induced immunosuppression.(2) Moreover, we hypothesize that one of the mechanisms through which NCT may act is by modulating the expression of cyclooxygenase (COX)-2, the rate-limiting enzyme in prostaglandin (PG) generation. This article is protected by copyright. All rights reserved

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here